Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

Trial Profile

Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 23 Apr 2018 Status changed from recruiting to withdrawn prior to enrolment as the Reseach got cancelled.
    • 02 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top